A comparative PET/CT study of Aß plaques tracers with asymmetric azines and [11C]-PiB in patients with mild to moderate Alzheimer's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400079771

Enrollment

Unknown

Registered

2024-01-11

Start date

2020-08-13

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Gold Standard:CDR or MMSE test shows the performance of cognition impairment

Positive results of [11C]-PiB

Index test:Compare the difference between the PET imaging results of the new 18F-labeled Aß plaque imaging agents and [11C]-PiB in enrolled subjects, and the difference of distributed patterns between

Calculation of Standard uptake value (SUV) and standard uptake value ratio (SUVR) of the new 18F-labeled Aß plaque imaging agents and [11C]-PiB in different regions of interest.

Eligibility

Sex/Gender

All

Age

55 Years to 75 Years

Inclusion criteria

Inclusion criteria: According to Petersen and other diagnostic criteria, AD subjects were included in the following criteria: (1) The subjects or their family members complained of obvious memory impairment; (2) Objective memory impairment (such as object memorization, recall, delayed memory, etc.); ?CDR=0.5; ?MMSE 11-26 points; Meet DSM IV and NINCDS-ADRDA Alzheimer's disease dementia criteria. The entry criteria of healthy control group included: ? overall health status; ?CDR=0; ? No complaints of memory impairment. Cognitive function was normal by the combined screening of MMSE (28-30 points) and MOCA (26-30 points).

Exclusion criteria

Exclusion criteria: In addition to the usual exclusion criteria for MRI use (such as endovascular medical devices, such as aneurysm clips), the exclusion criteria for all groups included: ? history of stroke, HIS > 4 points; ? Alcohol addiction; (3) Major mental illnesses: including anxiety disorders, emotional disorders, major psychosis, or drug-induced psychosis; Neurological diseases: including brain tumors, craniocerebral trauma, multiple sclerosis, epilepsy, etc. (5) Serious medical conditions, currently using respiratory drugs, cardiovascular drugs, anticonvulsants or psychoactive substances; ? Severe hearing and visual impairment.

Design outcomes

Primary

Measure	Time frame
Standard uptake value ratio (SUVR);Positron emission tomography;Standard uptake value in non-target brain regions;Standard uptake value in regions of interest;	—

Countries

China

Contacts

Public ContactJinming Zhang

Department of Nuclear Medicine, The First Medical Center, PLA General Hospital

zhangjm301@163.com+86 138 0121 0291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026